Abstract 34P
Background
Resilience to stress is a central phenotype underlying cancer cell biology. Cancer resilience empowers cell growth and survival in the face of harsh microenvironments, cytotoxic therapies, and loss of normal cellular regulatory processes. By understanding the mechanisms underlying cancer cell resilience, we may develop therapies which constrain tumors generally or synergize with existing drugs. Here, we sought to identify yet-unknown mechanisms by which cancer cells orchestrate resilience.
Methods
Using genome-scale CRISPR-Cas9 screening data from over 700 unique cancer cell lines (DepMap project), we developed a guilt-by-association “coessentiality” approach to identify genes involved cellular stress response signaling. We then used a combination of molecular biology, evolutionary biology, and computational biology approaches to validate predictions.
Results
Using an unbiased functional genomic approach and subsequent molecular validation, we identified HAPSTR1 (formerly: C16orf72) as a gene which becomes particularly important to cancer cells under stress conditions (e.g., DNA damage, protein aggregation, nutrient starvation). HAPSTR1, despite conservation through worms, yeast, and plants, had no known function. We found that HAPSTR1 encodes a dimeric protein which enables nuclear localization of HUWE1, an otherwise cytoplasmic ubiquitin ligase. Additionally, we show that mammals have a second HAPSTR gene, HAPSTR2 (formerly: RP11-364B14.3), which formed via an atypical evolutionary mechanism and functions to buffer the HAPSTR-HUWE1 pathway in specific cancer subsets.
Conclusions
Altogether, we present a new gene family and biochemical pathway leveraged by cancer cells to empower resilience. Disruption of this pathway broadly impairs stress response regulation and may thus be relevant to understanding and targeting resilience in human tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Institutes of Health (NIH-USA).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1792P - Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain
Presenter: Manuel Cobo Dols
Session: Poster session 07
1793P - Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1794P - Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC
Presenter: Lydia Meder
Session: Poster session 07
1795P - Consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: Preliminary analysis of phase II ASTRUM-LC01 study
Presenter: Yuqi Wu
Session: Poster session 07
1796P - Smoking-related genomic mutation patterns in patients with small cell lung cancer treated in ASTRUM-005 study
Presenter: Ying Cheng
Session: Poster session 07
1798P - Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1799P - Efficacy and safety of integrating consolidative thoracic radiotherapy with immunochemotherapy in ES-SCLC: A real-world retrospective analysis
Presenter: Qi Zhang
Session: Poster session 07
1800P - Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations
Presenter: Carminia Della Corte
Session: Poster session 07
1801P - Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
Presenter: Kenneth O'Byrne
Session: Poster session 07